 Connection
Mary Weiser-Evans to Heart Failure
This is a "connection" page, showing publications Mary Weiser-Evans has written about Heart Failure.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.285 |
|
|
|
-
McNair BD, Polson SM, Shorthill SK, Yusifov A, Walker LA, Weiser-Evans MCM, Kovacs EJ, Bruns DR. Metformin protects against pulmonary hypertension-induced right ventricular dysfunction in an age- and sex-specific manner independent of cardiac AMPK. Am J Physiol Heart Circ Physiol. 2023 08 01; 325(2):H278-H292.
Score: 0.087
-
Ambardekar AV, Stratton MS, Dobrinskikh E, Hunter KS, Tatman PD, Lemieux ME, Cleveland JC, Tuder RM, Weiser-Evans MCM, Moulton KS, McKinsey TA. Matrix-Degrading Enzyme Expression and Aortic Fibrosis During Continuous-Flow Left Ventricular Mechanical Support. J Am Coll Cardiol. 2021 11 02; 78(18):1782-1795.
Score: 0.078
-
Ambardekar AV, Weiser-Evans MCM, Li M, Purohit SN, Aftab M, Reece TB, Moulton KS. Coronary Artery Remodeling and Fibrosis With Continuous-Flow Left Ventricular Assist Device Support. Circ Heart Fail. 2018 05; 11(5):e004491.
Score: 0.061
-
Moulton KS, Li M, Strand K, Burgett S, McClatchey P, Tucker R, Furgeson SB, Lu S, Kirkpatrick B, Cleveland JC, Nemenoff RA, Ambardekar AV, Weiser-Evans MC. PTEN deficiency promotes pathological vascular remodeling of human coronary arteries. JCI Insight. 2018 02 22; 3(4).
Score: 0.060
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|